Shorter Hormone Therapy With Radiation for Selected People With High-Risk Prostate Cancer

Trial details

Who runs it

Dr. Tamim Niazi

Trial code

NCT07777263

Record updated

20 August 2026

Original description

High-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer.Read full original descriptionShow less

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study: A Phase III Trial Randomized Trial (PCS XIV)

High-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer.

ADT is usually given for 18 to 24 months, but it can cause side effects that may affect quality of life.

Some people with high-risk prostate cancer may do just as well with a shorter course of ADT. This study will identify people who are most likely to benefit from shorter treatment using imaging scans and tumor tests. It will then evaluate whether a shorter course of ADT works as well as the standard treatment while reducing long-term side effects.

Inclusion: • Able to understand and sign informed consent form (ICF); Males aged ≥ 18 years; Histologically confirmed adenocarcinoma of the prostate; Participants with high-risk prostate cancer according to either of the following:; High-risk disease - at least one of the following: i. T3a ii. Gleason 8 or less iii. PSA ≤ 30 ng/mL; Gleason 9 (4+5) not more than 30% of the biopsy (e.g. a 10-needle biopsy can only have a maximum of 3 x 9 [4+5]); PTEN-proficient tumor confirmed by CLIA-certified immunohistochemistry (IHC); PSMA-PET within 90 days prior to randomization: negative for nodal or distant disease; Candidate for definitive radiation to prostate and pelvis; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or Karnofsky performance status of ≥70%; Testosterone ≥150 ng/dL or 5 nmol/L; Adequate hematologic, renal, liver function (Hemoglobin ≥10 g/dL, Absolute Neutrophil Count ≥1.5x10⁹/L, Platelets ≥100x10⁹/L); Judged to be medically fit for ADT and RT; Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up; Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.

Exclusion: • Prior local or systemic therapy for prostate cancer (e.g. ADT, chemotherapy or novel Androgen Receptor Inhibitors [ARIs]); PSMA-PET positive nodal or distant metastases; PTEN loss or equivocal by IHC (at least more than 50%); Evidence of nodal or distant metastases on conventional imaging; Prior pelvic radiation or prostate surgery interfering with RT (except biopsy/TURP); Life expectancy <5 years regardless of the prostate cancer; Severe concurrent disease, infection, or co-morbidity that would make the patient inappropriate for enrollment (e.g. cardiovascular disease, hypertension, diabetes, etc); Uncontrolled cardiovascular disease including:; Myocardial infarction within 6 months; Unstable angina; Congestive Heart Failure: New York Heart Association (NYHA) class III or IV; Severe arrhythmia; Active severe infection or immunocompromised; Active second malignancy within 5 years with the exception of:; Non-melanoma skin cancer; Chronic Lymphocytic Leukemia (CLL) that is stable and not actively treated; Any condition compromising adherence to the protocol.

ClinicalTrials.gov NCT07777263